Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 3, 1997

View Archived Issues

Spotlight on Na+/H+-exchange inhibitors

Spotlight on endothelin receptor antagonists in cardiovascular medicine

Strakan exercises option to develop Access drug delivery technology

Merck & Co. describes nonsteroidal antiandrogen

Injectable drug delivery systems based on biodegradable block copolymers

Preclinical results with L-FMAU, an anti-HBV agent

LT antagonist/antihistamine combination highly effective against EAR/LAR

First launch for Roche's Posicor

Crinone launched in the U.S.

Tasmar launched in U.K., Germany

Pfizer identifies potent cholesterol absorption inhibitors

Cloning of telomerase catalytic subunit reported

UDCA suppresses allograft rejection after heart transplant

Long-term U.S. clinical trial results for orlistat reported in Stockholm

PAI-1 effective for evaluation of heart disease in women

Exercise is indicated for patients with weak hearts

More attention should be paid to cholesterol in heart disease patients, researchers say

VEGF prevents in-stent restenosis in rabbits

First approval for Zeneca's Seroquel

Alcohol abuse and atherosclerosis

Carbohydrate-based antimicrobial agents from Novo Nordisk

Leucomycin analogues reported by Meiji Seika

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.